跳至主要内容
临床试验/NCT03135041
NCT03135041已完成不适用

Effects of a Combination of Prebiotic Fibres on Weight Loss During an Energy Restricted Diet in an Overweight/Obese Population

University of Copenhagen2 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2017年5月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
117
试验地点
2
主要终点
Weight loss

研究概览

简要总结

The aim of this study is to investigate whether a diet supplemented with two prebiotic fibres induces greater changes in body weight compared to placebo during 12 weeks of energy restriction in an obese/overweight population.

The hypothesis is that the fiber-containing dietary supplement will:

  1. Induce greater changes in body weight compared to the placebo group 2) change the gut microbiota composition 3) improve glucose homeostasis 4) decrease serum concentration of triglycerides, total and LDL cholesterol

The hypothesis is that the effect of the intervention on weight loss will be partly mediated by the diet-induced changes in the gut microbiota composition.

详细描述

Prebiotics are nutrients that specifically utilized by the gut microbiota. Beneficial health effects of prebiotics are generally attributed to 1) stimulation of beneficial bacteria and SCFA production, and consequently; improved barrier function, regulation of enteroendocrine peptide secretion and resistance to inflammatory stimuli; 2) modulation of lipid metabolism, possibly by suppression of lipogenic enzymes and thus decreased synthesis of lipoproteins and triglycerides; and 3) increased mineral absorption.

Inulin is recognized as a common prebiotic. Fibersol-2 is a resistant starch that has been suggested to induce satiety, when given in a dose of 10 g. Intake of inulin has been shown to induce changes in the microbial abundance and increase production of SCFA19; whereas resistant starch has been shown to improve insulin sensitivity and postprandial glucose AUC20. However, the effects of an intervention with a combination of these two fibers on obesity and body composition during an energy restricted diet have not been addressed. Supplements with other types of fibres in addition to energy restriction have shown additional effects in weight reduction.

In this study, the effects of a combination product of two prebiotic fibres on additional weight loss during energy restriction in a placebo-controlled, randomized parallel study with a duration of 12 weeks will be tested. Furthermore, the effects of the fibres on the gut microbial composition, markers of metabolic syndrome (MetS) and glucose metabolism will be tested. The active diet will contain intervention products high in dietary fibre and the placebo diet will contain maltodextrin. The fiber-containing dietary supplements will add approximately 20 g of prebiotic fibres per day, where approximately 10 g will be inulin and approximately 10 g will be resistant maltodextrin. The intervention products and placebo will be consumed as milk. The fiber-containing dietary supplement is expected to induce additional weight loss, compared to placebo and to affect the gut microbiome and markers of metabolic disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • BMI: 28-45 kg/m2
  • Non-smoking
  • Haemoglobin level ≥7 mmol/L

排除标准

  • Use of antibiotics three months prior to study and during the study. If a participant uses antibiotics prior to randomization, the participant will be invited to be re-screened 3 months after the last use of antibiotics, provided that it is realistic to complete the study no later than the scheduled LPLV
  • Weight change >3 kg two months prior to study
  • Blood donation other than for this study <1 month prior to study and during study.
  • Participation in clinical trials other than for this <1 month prior to study and during study
  • Intensive physical training/ elite athlete (>10 hours of strenuous physical activity per week)
  • Unstable medication for dyslipidaemia and elevated blood pressure (the participant must have had a stable dose in the three months prior to study start), and use of systemic glucocorticoids
  • Medication for T2D
  • Treatment with metformin
  • Dietary supplements with pro- and/or prebiotics and/or fibre 6 weeks prior to study
  • Special dietary regimen (vegetarians, vegans etc.), as evaluated by study staff
  • Lactose intolerance or allergy to components in the intervention products
  • Gluten intolerance
  • Maltodextrin intolerance
  • Lactation, pregnancy or planning of pregnancy during the study
  • Gastro intestinal and liver disorders
  • Chronic inflammation disorders (excluding obesity)
  • Diagnosed psychiatric disorder including depression requiring treatment
  • Surgical treatment of obesity and abdominal surgery
  • Inability, physically or mentally, to comply with the procedures required by the study protocol, as evaluated by the study staff

研究组 & 干预措施

Fiber-containing dietary supplement

Experimental

2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction

干预措施: Fiber-containing dietary supplement (Dietary Supplement)

Placebo

Placebo Comparator

2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Weight loss

时间窗: Measurements will be performed at baseline and after 12 weeks of intervention

Differences in changes in body weight between the group that receives fiber-containing dietary supplement and placebo group

次要结局

  • Body composition(Measurements will be performed at baseline and after 12 weeks of intervention)
  • Gut microbiota composition and function(Measurements will be performed at baseline and after 12 weeks of intervention)
  • Glucose metabolism(Measurements will be performed at baseline and after 12 weeks of intervention)
  • Lipid metabolism(Measurements will be performed at baseline and after 12 weeks of intervention)
  • Inflammatory markers(Measurements will be performed at baseline and after 12 weeks of intervention)
  • SCFA concentration(Measurements will be performed at baseline and after 12 weeks of intervention)
  • Lipidomics and bile acids(Measurements will be performed at baseline and after 12 weeks of intervention)
  • Metabolomics(Measurements will be performed at baseline and after 12 weeks of intervention)
  • Weight loss(Measurements will be performed at baseline and after 12 weeks of intervention)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Thomas Meinert Larsen

Associate Professor, PhD

University of Copenhagen

研究点 (2)

Loading locations...

相似试验